Dayvigo Cost in Idaho 2026: Lemborexant Prices, Coverage, and Savings

What Is Dayvigo and How Was It Approved?

Dayvigo (lemborexant) is a dual orexin receptor antagonist approved by the FDA on December 20, 2019, for adults with insomnia characterized by difficulty with sleep onset or maintenance. It blocks both OX1R and OX2R receptors, reducing the brain's wake-promoting signals rather than broadly suppressing the central nervous system the way older sedative-hypnotics do. Prescribers can access the full Dayvigo prescribing information through the FDA label database.

The key SUNRISE-1 trial, published in JAMA Network Open (N=291 adults with insomnia disorder), demonstrated that lemborexant 5 mg and 10 mg both produced statistically significant reductions in subjective sleep onset latency compared with placebo at month 1 (P<0.001 for both doses). [1] The longer SUNRISE-2 trial extended these findings to 12 months, showing sustained efficacy without evidence of tolerance at either approved dose. [2]

The American Academy of Sleep Medicine (AASM) 2023 clinical practice guideline states: "We suggest that clinicians use lemborexant as a treatment for sleep onset and sleep maintenance insomnia in adults." That conditional recommendation reflects moderate-quality evidence from two well-conducted Phase 3 programs. [3]

Lemborexant is classified as a Schedule IV controlled substance by the DEA, the same tier as suvorexant (Belsomra) and most benzodiazepine-receptor agonists. Prescribing in Idaho therefore requires a valid DEA registration and a legitimate patient-prescriber relationship.

The standard starting dose is 5 mg taken no more than once per night, within 30 minutes of the intended sleep time, with at least 7 hours remaining before planned awakening. The 10 mg dose is available for patients who tolerate 5 mg but need additional effect. The FDA label warns against use with strong or moderate CYP3A inhibitors due to increased lemborexant exposure. [4]

How Much Does Dayvigo Cost in Idaho in 2026?

The cash cost of Dayvigo in Idaho in 2026 ranges from approximately $85 to $320 per month depending on which pricing channel the patient uses. Eisai's wholesale acquisition cost (WAC) is approximately $320 per month, but almost no cash-pay patient in Idaho pays that figure.

Idaho retail pharmacies, including major chains such as Walgreens, Walmart, and Fred Meyer, typically price Dayvigo between $300 and $340 per month at full retail before any discount program. Applying a GoodRx or RxSaver coupon reduces that figure to approximately $85 per month at many Idaho locations in 2026, which is a substantial but not universal discount. Prices vary by ZIP code: rural Idaho pharmacies in counties like Lemhi or Custer may see less competition, and coupon acceptance rates differ by chain.

The FDA's guidance on drug pricing transparency does not require pharmacies to proactively offer coupon pricing; patients must present the coupon themselves. [5] Downloading the GoodRx app, entering your Idaho ZIP code, and comparing prices at nearby pharmacies before filling the prescription takes under five minutes and can save more than $200 per month.

Specialty mail-order pharmacies affiliated with Eisai's patient support programs sometimes offer additional savings on top of coupon pricing. The exact amount depends on insurance status and household income, as described in the Eisai savings card section below.

For Idaho patients with commercial insurance that covers Dayvigo, out-of-pocket costs depend entirely on the plan's formulary tier. Dayvigo sits on Tier 3 or Tier 4 in most commercial formularies nationally, putting the typical copay between $50 and $120 per month after deductible. Checking the specific plan's formulary before the prescription is sent to the pharmacy avoids surprise costs at the counter.

Does Idaho Medicaid Cover Dayvigo?

Idaho Medicaid does not cover Dayvigo (lemborexant) as of 2026. The Idaho Department of Health and Welfare's preferred drug list does not include lemborexant, and no published prior-authorization pathway exists for it under the standard Idaho Medicaid benefit. [6]

This is consistent with Medicaid coverage patterns nationally. Orexin receptor antagonists have faced pushback from state Medicaid programs due to acquisition cost. Idaho's Medicaid program does cover older sedative-hypnotics, including zolpidem (generic, immediate-release) and temazepam (generic), both of which appear on the preferred drug list without prior authorization.

Dual-eligible Idaho patients (Medicare plus Medicaid) should check their Medicare Part D plan separately. Part D formulary placement for Dayvigo varies by plan sponsor; some Part D plans operating in Idaho do list lemborexant with prior authorization. The CMS Medicare Plan Finder tool at medicare.gov allows beneficiaries to compare 2026 Part D formularies before enrolling.

Idaho Medicaid does not currently cover compounded versions of lemborexant either, even when compounded by a licensed 503A pharmacy. Patients who cannot afford Dayvigo at retail and do not qualify for the Eisai savings card should discuss alternative insomnia medications or the compounded path described later in this article with their prescriber. [7]

The 2022 AASM position statement on chronic insomnia management emphasizes that "access to effective pharmacotherapy should not be determined solely by a patient's insurance status," a principle that underscores the importance of knowing every available pricing option before abandoning a clinically appropriate medication. [3]

Which Commercial Insurance Plans Cover Dayvigo in Idaho?

Commercial insurance coverage of Dayvigo in Idaho is inconsistent but more common than Medicaid coverage. Idaho's largest commercial payers, including Regence BlueShield of Idaho, Blue Cross of Idaho, PacificSource, and SelectHealth, each maintain their own formularies that change annually.

Regence BlueShield of Idaho listed lemborexant as a Tier 3 non-preferred brand on most 2025 formularies, typically requiring a step-edit through at least one preferred sleep medication (usually generic zolpidem) before approving Dayvigo. PacificSource similarly requires step therapy in Idaho. The step-edit requirement can be waived if the prescriber documents a clinical reason why first-line agents are contraindicated or have already failed. [8]

Idaho employers who self-insure under ERISA plans are not bound by Idaho state insurance mandates and set their own formularies. Smaller Idaho employers using fully insured ACA-compliant plans must cover prescription drugs as an essential health benefit, but specific formulary placement is still at insurer discretion.

The most reliable way to verify coverage before prescribing is a real-time formulary check through the pharmacy benefit manager (PBM) portal. Most Idaho prescribers have access to Surescripts or a PBM eligibility tool inside their EHR. Alternatively, the patient can call the member services number on the back of their insurance card and ask: "Is lemborexant (NDC 62856-0705-30 for the 5 mg or 62856-0706-30 for the 10 mg) covered on my 2026 formulary, and what are the step-therapy requirements?"

How Does the Eisai Savings Card Work in Idaho?

The Eisai Dayvigo Savings Card can reduce out-of-pocket cost to as low as $0 per month for commercially insured Idaho patients who meet eligibility criteria. Idaho patients with Medicaid, Medicare, or other federal or state government insurance are not eligible for the savings card, consistent with federal anti-kickback provisions.

Eligible commercially insured Idaho patients can enroll at DayvigoPro.com or by calling 1-855-423-6926. Once enrolled, the card functions like a secondary payer: the patient presents both their insurance card and the savings card at the pharmacy. The copay amount after insurance is applied is then reduced, sometimes to $0, up to a monthly benefit cap that Eisai adjusts annually.

For Idaho patients who are uninsured (cash-pay), Eisai offers a separate patient assistance program, the Eisai Patient Assistance Program (EPAP). Eligibility is income-based and requires documentation. Patients who qualify may receive Dayvigo at no cost through a 90-day supply shipped directly by Eisai. Application materials are available through NeedyMeds (needymeds.org) or directly through the Eisai medical affairs line.

The savings card does not stack with government insurance, but it does stack with most commercial copay assistance. An Idaho patient paying a $90 Tier 3 copay under a Regence plan, for example, may bring that cost to $0 with the card, subject to the monthly cap. Confirming the cap amount before relying on this benefit for the year is wise, as Eisai has revised these limits in prior years. [9]

Is Compounded Lemborexant Legal in Idaho?

Compounded lemborexant is legal in Idaho when prepared by a state-licensed 503A compounding pharmacy operating under a valid patient-specific prescription from a licensed prescriber. [10]

Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional patient-specific compounding pharmacies. A 503A pharmacy in Idaho may compound lemborexant as a non-commercially-available formulation (for example, a lower dose or an alternative oral form) when there is a valid prescription and a documented patient-specific clinical need. Bulk compounding for office stock or compounding a preparation that is essentially identical to the commercially available Dayvigo tablet without a patient-specific clinical justification falls outside the 503A exemption and would be considered illegal under federal law. [10]

The Idaho Board of Pharmacy regulates 503A pharmacies operating within Idaho's borders. Out-of-state 503A pharmacies shipping compounded lemborexant to Idaho patients must hold licensure in Idaho as a non-resident pharmacy. Patients should verify licensure status through the Idaho Division of Occupational and Professional Licenses (dopl.idaho.gov) before ordering from any out-of-state compounder.

503B outsourcing facilities (which produce larger batch quantities) are currently prohibited from compounding lemborexant because the active pharmaceutical ingredient (API) has not appeared on the FDA's 503B bulks list for orexin-pathway compounds. [11] This means the only legal compounding path in Idaho runs through 503A pharmacies with individual patient prescriptions.

Cost for compounded lemborexant at a licensed Idaho 503A pharmacy varies but is often substantially below the $85 retail cash price. Some compounding pharmacies quote prices in the range of $40 to $60 per month for a patient-specific formulation, though exact pricing depends on the dose, formulation vehicle, and pharmacy overhead. A formal written prescription identifying the patient, the compounding rationale, and the precise formulation is required for every fill.

The HealthRX clinical team uses the following decision framework when evaluating compounded lemborexant for Idaho patients:

1. Confirm the prescribing clinician holds an active Idaho DEA registration (Schedule IV).
2. Verify the compounding pharmacy holds an Idaho Board of Pharmacy license (503A designation).
3. Document the patient-specific clinical rationale (for example, sensitivity to tablet excipients or a dose not commercially available).
4. Confirm that the compounded formulation contains pharmaceutical-grade API with a certificate of analysis from the API supplier.
5. Review the patient's other medications for CYP3A4 interactions before finalizing the dose.

Can I Get Dayvigo via Telehealth in Idaho?

Telehealth prescribing of Dayvigo is legal in Idaho as of 2026. Idaho amended its telehealth practice standards in alignment with post-pandemic DEA rules, and Schedule IV controlled substances, including lemborexant, may be prescribed via synchronous audio-visual telehealth when a valid patient-prescriber relationship exists. [12]

Idaho Code Section 54-5703 defines a valid patient-prescriber relationship as one in which the prescriber has gathered sufficient information to establish a diagnosis, consistent with the standard of care, either in person or through an appropriate telehealth encounter. A synchronous video visit that includes a sleep history, review of prior treatments, Epworth Sleepiness Scale documentation, and a medication reconciliation meets that standard for most Idaho prescribers.

The DEA's 2023 telemedicine rules, finalized after the COVID-19 Public Health Emergency ended, permit Schedule IV prescriptions via telemedicine for patients who have had at least one in-person visit with any DEA-registered practitioner. Idaho telehealth companies operating nationally, including HealthRX, are required to comply with both federal DEA rules and Idaho Board of Pharmacy regulations when prescribing and dispensing lemborexant to Idaho residents. [13]

Patients in rural Idaho counties such as Owyhee, Clark, or Adams, where sleep medicine specialists are not locally available, stand to benefit most from telehealth access to Dayvigo prescriptions. The FDA's approved label does not require polysomnography before prescribing lemborexant, so a telehealth clinician can initiate therapy based on a thorough history alone, consistent with AASM guideline recommendations. [3]

What Does the Clinical Evidence Say About Lemborexant's Effectiveness?

The SUNRISE-1 trial (N=291, 30-day treatment, published JAMA Network Open 2019) established lemborexant's efficacy over placebo and over zolpidem extended-release 6.25 mg. [1] At month 1, the lemborexant 10 mg arm reduced subjective sleep onset latency (sSOL) by a mean of 17.4 minutes from baseline, compared with 9.2 minutes for placebo (P<0.001). The lemborexant 5 mg arm reduced sSOL by 14.9 minutes (P<0.001). Next-morning residual sleepiness, measured by the Karolinska Sleepiness Scale, was significantly lower with lemborexant 5 mg than with zolpidem ER at hour 9 post-dose (P<0.05). [1]

SUNRISE-2 (N=949, 12-month double-blind phase) confirmed that efficacy did not diminish over 12 months of nightly use. Wake after sleep onset (WASO) remained significantly lower in both lemborexant arms than in the placebo arm throughout the study period, including at the month-12 primary endpoint (P<0.001 for both doses). [2]

A 2021 network meta-analysis published in the Annals of Internal Medicine evaluated 30 pharmacological agents for insomnia across 154 randomized controlled trials (N=44,089 participants). Lemborexant ranked among the top agents for sleep maintenance efficacy with a favorable next-day functioning profile relative to benzodiazepines and z-drugs. [14]

The FDA label documents the most common adverse events as somnolence (10% at 5 mg, 10% at 10 mg versus 7% placebo) and headache (6% vs. 5% placebo). Complex sleep behaviors, including sleepwalking and sleep-driving, have been reported with all approved sleep aids and carry an FDA boxed warning for the class. [4]

For Idaho patients with mild-to-moderate hepatic impairment, the 5 mg dose is the maximum recommended dose. Lemborexant is not recommended for patients with severe hepatic impairment. These restrictions are particularly relevant for Idaho patients who co-prescribe lemborexant with agents metabolized by CYP3A4. [4]

What Is the Cheapest Way to Get Dayvigo in Idaho?

For most Idaho patients, the cheapest legal path to lemborexant in 2026 is one of three routes, depending on insurance status.

Commercially insured Idaho patients should combine their insurance benefit with the Eisai savings card. This combination can reduce monthly out-of-pocket cost to $0 for patients whose plan covers Dayvigo at any tier. A step-edit denial should be appealed with documentation of prior treatment failure rather than abandoned. [8]

Cash-pay Idaho patients without government insurance should start with a GoodRx coupon at a high-volume retail pharmacy. The $85-per-month price point is achievable at multiple Idaho locations. Comparing prices across pharmacies in the same city using GoodRx's comparison tool before sending the prescription takes minutes and sometimes yields prices below $85 at warehouse pharmacies such as Costco (which is open to non-members for pharmacy services in Idaho). [15]

Idaho patients who qualify for the Eisai Patient Assistance Program pay nothing for Dayvigo. Income thresholds and application requirements are updated annually; the current threshold is typically set at or below 400% of the federal poverty level for full assistance. [9]

Compounded lemborexant from a licensed Idaho 503A pharmacy represents a fourth option for patients with a documented clinical need for a non-standard formulation. Cost is typically below the retail cash price, though the legal and clinical requirements described above must be met.

Switching to a covered generic sedative-hypnotic such as zolpidem 5 mg or 10 mg, while clinically different from lemborexant, is sometimes appropriate when cost is the primary barrier. That decision belongs to the prescribing clinician, who can weigh prior treatment history, comorbidities, and patient preference. [3]